Axonics Modulation Technologies Inc at Morgan Stanley Healthcare Conference Transcript
Let's go ahead and get going here. My name is David Lewis, Medical & Devices Analyst here at Morgan Stanley. Thanks for joining us here for our -- at least my first session of Day 3 of the Morgan Stanley Healthcare Conference. It's my pleasure to have with us here, Axonics, and their CEO, Ray Cohen. And we're just going to jump straight into the Q&A.
Questions & Answers
There has been some exciting news this week, Ray, we'll certainly get into. But given the approval for -- the first step approval for fecal incontinence with the system, I thought it'd be nice to start off and remind people, it's been a long time coming, waiting for this approval since the IPO. So maybe just talk a little bit about the market, just really briefly. How you see the size of -- that's one is fecal incontinence, but maybe we can talk about the overactive bladder market and sort of how that disease population is treated for sort of first, second, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |